$ELDN
Eledon Pharmaceuticals, Inc.

2015 Q4 Form 10-Q Financial Statement

#000119312515372762 Filed on November 10, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.340M $3.420M $3.600M
YoY Change 35.77% -5.0% 445.45%
% of Gross Profit
Research & Development $7.730M $8.491M $2.825M
YoY Change 103.42% 200.57% 4.47%
% of Gross Profit
Depreciation & Amortization $60.00K $30.00K $10.00K
YoY Change 200.0% 0.0%
% of Gross Profit
Operating Expenses $11.07M $11.91M $6.424M
YoY Change 76.84% 85.35% 90.91%
Operating Profit -$11.07M -$11.91M -$6.424M
YoY Change 76.84% 85.35% 90.91%
Interest Expense $60.00K $50.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net $34.00K
YoY Change
Pretax Income -$11.02M -$11.85M -$6.390M
YoY Change 77.46% 85.45% 89.61%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$11.02M -$11.85M -$6.390M
YoY Change 77.46% 85.49% 89.9%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$78.71M -$84.64M -$49.15M
COMMON SHARES
Basic Shares Outstanding 22.58M shares 22.55M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $64.00M $73.10M $105.5M
YoY Change -39.22% -30.71%
Cash & Equivalents $24.02M $33.17M $105.5M
Short-Term Investments $39.90M $39.90M
Other Short-Term Assets $3.200M $3.800M $1.300M
YoY Change 39.13% 192.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $67.17M $76.87M $106.7M
YoY Change -37.52% -27.98%
LONG-TERM ASSETS
Property, Plant & Equipment $489.0K $427.0K $38.00K
YoY Change 1381.82% 1023.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $45.00K $45.00K $21.00K
YoY Change -77.5% 114.29%
Total Long-Term Assets $804.0K $742.0K $259.0K
YoY Change 245.06% 186.49%
TOTAL ASSETS
Total Short-Term Assets $67.17M $76.87M $106.7M
Total Long-Term Assets $804.0K $742.0K $259.0K
Total Assets $67.97M $77.61M $107.0M
YoY Change -36.91% -27.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.208M $1.652M $2.889M
YoY Change 57.91% -42.82%
Accrued Expenses $4.954M $4.005M $2.483M
YoY Change 42.44% 61.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.162M $5.657M $5.372M
YoY Change 45.23% 5.31%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $100.0K $0.00
YoY Change
Other Long-Term Liabilities $88.00K $51.00K
YoY Change
Total Long-Term Liabilities $88.00K $51.00K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.162M $5.657M $5.372M
Total Long-Term Liabilities $88.00K $51.00K $0.00
Total Liabilities $6.250M $5.708M $5.372M
YoY Change 47.3% 6.25%
SHAREHOLDERS EQUITY
Retained Earnings -$131.4M -$120.4M -$80.14M
YoY Change 52.21% 50.26%
Common Stock $193.2M $192.3M $22.00K
YoY Change 1.77% 874045.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.782M $71.90M $101.6M
YoY Change
Total Liabilities & Shareholders Equity $67.97M $77.61M $107.0M
YoY Change -36.91% -27.46%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$11.02M -$11.85M -$6.390M
YoY Change 77.46% 85.49% 89.9%
Depreciation, Depletion And Amortization $60.00K $30.00K $10.00K
YoY Change 200.0% 0.0%
Cash From Operating Activities -$8.880M -$10.25M -$4.460M
YoY Change 37.46% 129.82% 49.16%
INVESTING ACTIVITIES
Capital Expenditures -$220.0K -$160.0K -$10.00K
YoY Change 1500.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities -$100.0K -$15.70M -$150.0K
YoY Change 10366.67%
Cash From Investing Activities -$320.0K -$15.85M -$160.0K
YoY Change 9806.25% 700.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 190.0K 88.94M
YoY Change -99.36% -99.79% -889500.0%
NET CHANGE
Cash From Operating Activities -8.880M -10.25M -4.460M
Cash From Investing Activities -320.0K -15.85M -160.0K
Cash From Financing Activities 40.00K 190.0K 88.94M
Net Change In Cash -9.160M -25.91M 84.32M
YoY Change 4261.9% -130.73% -2892.05%
FREE CASH FLOW
Cash From Operating Activities -$8.880M -$10.25M -$4.460M
Capital Expenditures -$220.0K -$160.0K -$10.00K
Free Cash Flow -$8.660M -$10.09M -$4.450M
YoY Change 34.06% 126.74% 49.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1652000
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22584675 shares
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105464000
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22581545 shares
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22581545 shares
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
192289000
CY2015Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
105000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2291000
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
912000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
71899000
CY2015Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
51000
CY2015Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
597000
CY2015Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4005000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120421000
CY2015Q3 us-gaap Liabilities
Liabilities
5708000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77607000
CY2015Q3 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
23000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5657000
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8000
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000
CY2015Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2015Q3 us-gaap Assets
Assets
77607000
CY2015Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
68341000
CY2015Q3 us-gaap Investments And Cash
InvestmentsAndCash
73103000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
427000
CY2015Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
270000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
76865000
CY2015Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
39935000
CY2015Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39927000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3762000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33168000
CY2015Q3 tkai Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2391000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31753000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22382340 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22382340 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
189830000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
165000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
963000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
103501000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
497000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
765000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3478000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86351000
CY2014Q4 us-gaap Liabilities
Liabilities
4243000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107744000
CY2014Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4243000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33272000
CY2014Q4 us-gaap Assets
Assets
107744000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
91316000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
200000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
107511000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2255000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105256000
CY2014Q4 tkai Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1853000
CY2014Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
14860173 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14661000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.19
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2879313 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1124627 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Net Income Loss
NetIncomeLoss
-17088000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
835000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1974000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17201000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
21000
us-gaap Allowance For Loan And Lease Losses Adjustments Net
AllowanceForLoanAndLeaseLossesAdjustmentsNet
113000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
150000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17088000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
361000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
73711000
us-gaap Operating Expenses
OperatingExpenses
17201000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-175000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
88547000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10773000
us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
113000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-23000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
12000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1519000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6428000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
90396000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1884000
us-gaap Depreciation
Depreciation
16000
tkai Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
113000
tkai Conversion Of Redeemable Convertible Preferred Stock Into Common Stock
ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock
85345000
tkai Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
1302000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-32359000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.52
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2359606 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001404281
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.00 pure
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
TOKAI PHARMACEUTICALS INC
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates, assumptions and judgments reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#x2019;s estimates.</p> </div>
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
416000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2044000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9284000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
887000
us-gaap Depreciation
Depreciation
53000
dei Trading Symbol
TradingSymbol
TKAI
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22449484 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
349000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
39775000
us-gaap Net Income Loss
NetIncomeLoss
-34070000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1507000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34189000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
45000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
8000
us-gaap Allowance For Loan And Lease Losses Adjustments Net
AllowanceForLoanAndLeaseLossesAdjustmentsNet
49000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
70000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34062000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
98000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
34000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
661000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-72088000
us-gaap Operating Expenses
OperatingExpenses
34189000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-40194000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
465000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24905000
us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
49000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
429000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
51000
tkai Earliest Year Open For Tax Examination
EarliestYearOpenForTaxExamination
2012
tkai Marketable Securities Premium On Securities Purchased
MarketableSecuritiesPremiumOnSecuritiesPurchased
186000
tkai Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
119000
tkai Increase Decrease In Deferred Tax Assets
IncreaseDecreaseInDeferredTaxAssets
13000000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.71
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2357236 shares
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-6390000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6424000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6390000
CY2014Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2014Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
152000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
6424000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2825000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1179000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3599000
CY2014Q3 tkai Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
34000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22540876 shares
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-11853000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11907000
CY2015Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
10000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11843000
CY2015Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
10000
CY2015Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2015Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
174000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
11907000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8491000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
804000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3416000
CY2015Q3 tkai Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
54000

Files In Submission

Name View Source Status
0001193125-15-372762-index-headers.html Edgar Link pending
0001193125-15-372762-index.html Edgar Link pending
0001193125-15-372762.txt Edgar Link pending
0001193125-15-372762-xbrl.zip Edgar Link pending
d61517d10q.htm Edgar Link pending
d61517dex311.htm Edgar Link pending
d61517dex312.htm Edgar Link pending
d61517dex321.htm Edgar Link pending
d61517dex322.htm Edgar Link pending
d61517dex991.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g61517g25a35.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tkai-20150930.xml Edgar Link completed
tkai-20150930.xsd Edgar Link pending
tkai-20150930_cal.xml Edgar Link unprocessable
tkai-20150930_def.xml Edgar Link unprocessable
tkai-20150930_lab.xml Edgar Link unprocessable
tkai-20150930_pre.xml Edgar Link unprocessable